Filing Flows › Comparisons › RCUS vs LIFD
Arcus Biosciences vs Lftd Partners: RCUS and LIFD compared
Arcus Biosciences is the larger company: $9.0M of revenue in its latest quarter (Q3 2026) against $8.7M for Lftd Partners (Q2 2026). Lftd Partners is growing faster (-16% against -65% a year earlier).
Where the money goes: RCUS and LIFD
Arcus Biosciences (RCUS) · Q3 2026
Arcus Biosciences, Q3 2026: revenue $9.0M (-65% year over year), net loss $128M, operating cash flow −$88.0M. The chart follows the revenue to costs, profit and cash.
Lftd Partners (LIFD) · Q2 2026
Lftd Partners, Q2 2026: revenue $8.7M (-16% year over year), operating margin -17.5%, net loss $1.4M, operating cash flow −$555K. The chart follows the revenue to costs, profit and cash.
| Arcus Biosciences (RCUS) | Lftd Partners (LIFD) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $9.0M | $8.7M |
| Revenue growth, Y/Y | -65% | -16% |
| Operating margin | n/m | -17.5% |
| Net earnings | −$128M | −$1.4M |
| Net margin | — | -16.5% |
| Operating cash flow | −$88.0M | −$555K |
Where the revenue comes from
Arcus Biosciences
- License and development services: $8.0M (89%)
- Other collaboration: $1.0M (11%)
Lftd Partners
- Products to Distributors: $6.1M (70%)
- Products to End Consumers: $1.2M (14%)
- Products to Wholesalers: $962K (11%)
- Products to Private Label Clients: $361K (4%)
Questions
Which is bigger, Arcus Biosciences or Lftd Partners?
Arcus Biosciences is the larger company: $9.0M of revenue in its latest quarter (Q3 2026) against $8.7M for Lftd Partners (Q2 2026).
Is Arcus Biosciences or Lftd Partners growing faster?
Lftd Partners is growing faster (-16% against -65% a year earlier).
More: Arcus Biosciences earnings · how Arcus Biosciences makes money · Lftd Partners earnings · how Lftd Partners makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.